ROCHESTER, N.Y., March 13, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that it will be presenting at Oppenheimer & Co.’s 29th Annual Healthcare Conference on Tuesday, March 19th at 3:55PM ET in Track 2. Maurice Zauderer, Ph.D., president & CEO, will be presenting an update on the Company’s ongoing clinical development programs and will be available for meetings with investors.
The Oppenheimer & Co. 29th Annual Healthcare Conference will be held March 19-20, 2019 at the Westin New York Grand Central in New York City. Please contact conference organizers for investor meetings.
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders.
Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
Phone: 212-915-2568
Email: jeremy@lifesciadvisors.com
Media Contact
Jules Abraham
JQA Partners, Inc.
Phone: (917) 885-7378
E-mail: jabraham@jqapartners.com